首页 News 正文

Innovative medicine sector continues to recover, and the total product revenue of Zengding Pharmaceutical in the third quarter increased by over 20% year-on-year

海角七号
257 0 0

On November 8th, Zaiding Pharmaceutical released its Q3 financial report. Data shows that the total revenue of Zaiding Pharmaceutical's products in the third quarter was 69.228 million US dollars, a year-on-year increase of 21.53%, and a year-on-year increase of 27% calculated at a fixed exchange rate. Mainly due to the increase in sales, the official launch of the newly approved product Weiweijia, and a decrease in the negative impact of the COVID-19 pandemic.
Financial report data shows that compared to the same period in 2022, several heavyweight products of Zaiding Pharmaceutical have achieved strong growth.
In the third year of being included in the national medical insurance drug catalog, Zele continued to maintain its position as a leading hospital sales PARP inhibitor in the field of ovarian cancer in mainland China, with product revenue increasing from $39.2 million to $41.6 million. The revenue of Epshield products increased from $10.7 million to $11.6 million, thanks to the improved accessibility of the product for self funded patients. In addition, the revenue of the two products, Qingle and Newzele, which have already been included in medical insurance, both achieved year-on-year growth.
In September 2023, Weiweijia& was used in combination with conventional treatment drugs to treat adult gMG patients with acetylcholine (AChR) antibody positivity; Reg; (Agamod) α Injection) has been launched in mainland China, and the number of commercial products from Zaiding Pharmaceutical has increased to 5. In just one month of commercialization, Wei Weijia achieved sales revenue of $4.9 million.
In addition to existing products that have already been launched, Zaiding Pharmaceutical is still actively exploring the multiple indications coverage of products that have already been launched, as well as promoting the further implementation of research and development pipelines.
The company is also continuing to promote the development of its subsequent dosage forms for the heavyweight new drug Agamod in the field of self immunity, which has received considerable market attention. Zaiding Pharmaceutical stated that its drug application for the treatment of systemic myasthenia gravis is expected to be approved by the National Drug Administration in 2024.
Another product in the pipeline of the already launched products of Zaiding Pharmaceutical, tumor electric field therapy, is expected to receive multiple indications for market application and disclosure of main clinical research data by the end of 2023 and 2024.
In addition to exploring multiple indications for products that have already been launched, Zaiding Pharmaceutical also has multiple products in the fields of tumors, Alzheimer's disease and psychiatric disorders (ADP), which are about to usher in multiple important milestones and the latest research results in the coming year.
Founder of Zaiding Pharmaceutical Dr. Du Ying, Chairman and CEO, stated, "In the third quarter of 2023, we achieved multiple important milestones, including the National Drug Administration (NMPA) We are reviewing and approving multiple new drug launch applications from our company and conducting critical clinical studies on drugs with significant market potential. We have a good advantage in accelerating our pipeline progress, expanding our commercial product portfolio, and bringing more benefits to patients worldwide
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  •   知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
    caffycat
    昨天 11:18
    支持
    反对
    回复
    收藏
  •   每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
    star8699
    3 天前
    支持
    反对
    回复
    收藏
  •   上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
    goodfriendboy
    3 天前
    支持
    反对
    回复
    收藏
  •   人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
    3233340
    昨天 17:06
    支持
    反对
    回复
    收藏
海角七号 注册会员
  • 粉丝

    0

  • 关注

    1

  • 主题

    29